Pierre W. Wijermans

7.6k citations

69 papers · 3.7k indexed · h-index 24

Hematology top 0.2%
- Acute Myeloid Leukemia Research 32
- Multiple Myeloma Research and Treatments 11
- Hematopoietic Stem Cell Transplantation 10
Genetics top 2%
- Hemoglobinopathies and Related Disorders 8
Oncology top 5%
Molecular Biology top 5%
- Epigenetics and DNA Methylation 10
- Protein Degradation and Inhibitors 8
Public Health, Environmental and Occupational Health top 2%
- Acute Lymphoblastic Leukemia research 15
Physiology
- Erythrocyte Function and Pathophysiology 6

Co-authors: Michael Lübbert Björn Rüter Jan J. Cornelissen Marinus van Marwijk Kooy Pieter Sonneveld Bob Löwenberg Michael Daskalakis Augustin Ferrant
Cited by: Hematology Genetics Oncology
Journals: Journal of Clinical Oncology (5 papers)Blood (19 papers)The Journal of Immunology (2 papers)
Partner nations: Netherlands Germany Belgium

In The Last Decade

Pierre W. Wijermans

68 papers receiving 3.6k citations

Peers

Countries citing papers authored by Pierre W. Wijermans

Since Specialization

Citations

This map shows the geographic impact of Pierre W. Wijermans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre W. Wijermans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre W. Wijermans more than expected).

Fields of papers citing papers by Pierre W. Wijermans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre W. Wijermans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre W. Wijermans. The network helps show where Pierre W. Wijermans may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Pierre W. Wijermans, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Pierre W. Wijermans Line = papers co-authored together Pierre W. Wijermans links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia Annals of Hematology ·Heiko Becker,Dietmar Pfeifer,Gabriele Ihorst,Milena Pantić,Julius Wehrle,Björn Rüter,Lars Bullinger,Björn Hackanson,Ulrich Germing,Andrea Kuendgen,Uwe Platzbecker,Konstanze Döhner,Arnold Ganser,Anne Hagemeijer,Pierre W. Wijermans,Hartmut Döhner,Justus Duyster,Michael Lübbert	2020	11
2	Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study PLoS ONE ·Saskia Persoon,Mai J. M. Chinapaw,Laurien M. Buffart,Roberto D. K. Liu,Pierre W. Wijermans,Harry R. Koene,Monique C. Minnema,Pieternella J. Lugtenburg,Erik W.A. Marijt,Johannes Brug,Frans Nollet,Marie José Kersten	2017	73
3	Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG) Annals of Hematology ·Heiko Becker,Stefan Suciu,Björn Rüter,Uwe Platzbecker,Aristoteles Giagounidis,Dominik Selleslag,Boris Labar,Ulrich Germing,Helmut R. Salih,Petra Muus,Karl-Heinz Pflüger,Anne Hagemeijer,Hans‐Eckart Schaefer,Valeria Fiaccadori,Frédéric Baron,Arnold Ganser,Carlo Aul,Théo de Witte,Pierre W. Wijermans,Michael Lübbert	2015	16
4	Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study Cancer Chemotherapy and Pharmacology ·Robert S. Jansen,Hilde Rosing,Pierre W. Wijermans,Ron J. Keizer,Jan H.M. Schellens,Jos H. Beijnen	2012	14
5	Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials Blood ·Peter Fayers,Antonio Palumbo,Cyrille Hulin,Anders Waage,Pierre W. Wijermans,Meral Beksaç,Sara Galimberti,Jean–Yves Mary,Peter Gimsing,Fabian Termorshuizen,Rauf Haznedar,Tommaso Caravita,Philippe Moreau,Ingemar Turesson,Pellegrino Musto,Lotfi Benboubker,M. Ronald Schaafsma,Pieter Sonneveld,Thierry Façon,(unknown)	2011	179
6	‘Patient’s en doctor’s delay’ bij multipel myeloom en de ziekte van Waldenström Naomi van der Linden,Carin A. Uyl‐de Groot,Pierre W. Wijermans	2010	0
7	Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program Clinical Lymphoma Myeloma & Leukemia ·Evelien Kneppers,Henk M. Lokhorst,Corien Eeltink,Gerwin Huls,Marie José Kersten,Jan Koedam,Monique C. Minnema,Marinus H. J. van Oers,Reinier Raymakers,M. Ronald Schaafsma,Edo Vellenga,Pierre W. Wijermans,Shulamiet Wittebol,Pieter Sonneveld,Sonja Zweegman	2010	16
8	Hb Den Haag [β45(CD4)Phe→Tyr]. A New Hemoglobin Variant Observed During Early Pregnancy Diagnostics Hemoglobin ·Judith O. Kaufmann,Cornelis L. Harteveld,Margreet Bakker‐Verweij,Sandra G.J. Arkesteijn,Peter van Delft,Hans L. Haak,Pierre W. Wijermans,Jean‐Louis Kerkhoffs,Piero C. Giordano	2010	2
9	Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison Blood ·Jan J. Cornelissen,Bronno van der Holt,Gregor Verhoef,Mars B. van ’t Veer,Marinus H. J. van Oers,Harry C. Schouten,Gert J. Ossenkoppele,Pieter Sonneveld,Johan Maertens,Marinus van Marwijk Kooy,M Schaafsma,Pierre W. Wijermans,Douwe H. Biesma,Shulamit Wittebol,P.J. Voogt,Joke W. Baars,Pierre Zachée,Leo F. Verdonck,Bob Löwenberg,A. W. Dekker	2008	121
10	The clinical impact of platelet refractoriness: correlation with bleeding and survival Transfusion ·Jean‐Louis H. Kerkhoffs,Jeroen Eikenboom,Leo M.G. van de Watering,Rinie J. van Wordragen-Vlaswinkel,Pierre W. Wijermans,Anneke Brand	2008	90
11	Long‐term follow‐up of a population based cohort with monoclonal proteinaemia British Journal of Haematology ·C. G. Schaar,Saskia le Cessie,Simone Snijder,Paul Franck,Pierre W. Wijermans,Cisca Ong,Hanneke C. Kluin‐Nelemans	2008	14
12	Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood ·Jan J. Cornelissen,Wim L.J. van Putten,Leo F. Verdonck,Matthias Theobald,E Jacky,Simon Daenen,Marinus van Marwijk Kooy,Pierre W. Wijermans,Harry C. Schouten,Peter C. Huijgens,Hans van der Lelie,Martin F. Fey,Augustin Ferrant,Johan Maertens,Aloïs Gratwohl,Bob Löwenberg	2007	345
13	Superiority of prolonged low‐dose azanucleoside administration? Cancer ·Björn Rüter,Pierre W. Wijermans,Michael Lübbert	2006	50
14	Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: Lack of evidence for induction of chromosomal instability Leukemia Research ·Peter Haas,Pierre W. Wijermans,Gregor Verhoef,Michael Lübbert	2005	6
15	DNA Methylation as a Therapeutic Target in Hematologic Disorders: Recent Results in Older Patients with Myelodysplasia and Acute Myeloid Leukemia International Journal of Hematology ·Björn Rüter,Pierre W. Wijermans,Michael Lübbert	2004	53
16	A New Hb Evanston Allele [α14(A12)Trp → Arg] Found Solely, and in the Presence of Common α‐Thalassemia Deletions, in Three Independent Asian Cases Hemoglobin ·Cornelis L. Harteveld,Pierre W. Wijermans,Juliette E. L. M. de Ree,Pauline Ter Hal,Peter van Delft,Irene H. van Rooijen-Nijdam,Ellen Rasp,Peter J.M.J. Kok,John H. M. Souverijn,F. G. A. Versteegh,Piero C. Giordano	2004	10
17	A novel 7·9 kb deletion causing α⁺‐thalassaemia in two independent families of Indian origin British Journal of Haematology ·Cornelis L. Harteveld,Peter van Delft,Pierre W. Wijermans,M. C. Kappers‐Klunne,Jitske Weegenaar,Monique Losekoot,Piero C. Giordano	2003	9
18	Intermediate‐dose melphalan (IDM) combined with G‐CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma British Journal of Haematology ·Henk M. Lokhorst,Pieter Sonneveld,Pierre W. Wijermans,Marinus van Marwijk Kooy,Otger Th. Meuwissen,Rien van Oers,René Van Der Griend,A. W. Dekker	1996	20
19	Low dose cytosine-arabinoside has only minimal differentiation inducing capacity in HL60 cells European Journal of Cancer and Clinical Oncology ·G. J. Ossenkoppele,Pierre W. Wijermans,F. C. de Waal,Tineke A.M.V.D. Berg,Wim Jalink,Peter C. Huijgens,M. M. A. C. Langenhuijsen	1989	4
20	Changes in the expression of N‐acetylglucosaminyltransferase III, IV, V associated with the differentiation of HL‐60 cells FEBS Letters ·Anky H. L. Koenderman,Pierre W. Wijermans,Dirk H. van den Eijnden	1987	43

About Pierre W. Wijermans

Pierre W. Wijermans is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health, having authored 69 papers that have together received 3.7k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (32 papers), Acute Lymphoblastic Leukemia research (15 papers), Multiple Myeloma Research and Treatments (11 papers), Hematopoietic Stem Cell Transplantation (10 papers), Epigenetics and DNA Methylation (10 papers), Protein Degradation and Inhibitors (8 papers), Hemoglobinopathies and Related Disorders (8 papers) and Erythrocyte Function and Pathophysiology (6 papers). The work is most often cited by research in Hematology (2.4k citations), Genetics (576 citations) and Oncology (886 citations). Pierre W. Wijermans has collaborated with scholars based in Netherlands, Germany and Belgium. Frequent co-authors include Michael Lübbert, Björn Rüter, Jan J. Cornelissen, Marinus van Marwijk Kooy, Pieter Sonneveld, Bob Löwenberg, Michael Daskalakis, Augustin Ferrant, Gabriele Köhler and Carvell T. Nguyen. Their work appears in journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact